AIM To investigate Japanese traditional(Kampo) medicine's effectiveness on cancer chemotherapy-induced peripheral neuropathy(CIPN), we carried out this retrospective study.METHODS By searching our outpatient datab...AIM To investigate Japanese traditional(Kampo) medicine's effectiveness on cancer chemotherapy-induced peripheral neuropathy(CIPN), we carried out this retrospective study.METHODS By searching our outpatient database of 3154 patients who consulted our outpatient clinic of Japanese-Oriental(Kampo) Medicine at Chiba University Hospital from November 2005 to December 2010, a total of 281 patients diagnosed with cancer were identified. Twentyfour patients out of the 281 patients identified met the following three conditions and were eligible for further investigation of the effectiveness of Kampo treatment: At least one course of cancer chemotherapy had been administered; numbness and pain appeared after the chemotherapy; and CIPN was diagnosed before they were given Kampo treatment.RESULTS The 24 patients included 6 males and 18 females and ranged in age from 39 to 86(mean 61.2 ± 11.5) years old. Kampo formulas were individually chosen by Kampo expert doctors based on Kampo-specific diagnostics. Beneficial outcomes were obtained by Kampo treatment in 20 out of the 24 cases(83.3%). Nine out 20 cases had a major response(the numbness and pain showed improvement or reduction by 50% or more), with 7 of 9 cases showing a more than 70% symptom reduction. Eleven out of 20 cases showed a minor response(less than 50% symptom reduction), and 4 out of the 24 cases had no beneficial response. The most frequently used formula was goshajinkigan(GJG), followed by hachimijiogan(HJG) and keishibukuryogan. Thirteen of the 24 cases(54.2%) were prescribed aconite rootcontaining formulas including GJG and HJG. Aconite root has "warming" effects and ameliorates pain and numbness; 21 out of 24 cases(87.5%) in total used warming formulas such as aconite root-containing formulas to reduce CIPN.CONCLUSION Our current study suggested that Kampo formulas chosen based on Kampo-specific diagnostics could be for treating CIPN that is refractory to conventional medicine.展开更多
文摘AIM To investigate Japanese traditional(Kampo) medicine's effectiveness on cancer chemotherapy-induced peripheral neuropathy(CIPN), we carried out this retrospective study.METHODS By searching our outpatient database of 3154 patients who consulted our outpatient clinic of Japanese-Oriental(Kampo) Medicine at Chiba University Hospital from November 2005 to December 2010, a total of 281 patients diagnosed with cancer were identified. Twentyfour patients out of the 281 patients identified met the following three conditions and were eligible for further investigation of the effectiveness of Kampo treatment: At least one course of cancer chemotherapy had been administered; numbness and pain appeared after the chemotherapy; and CIPN was diagnosed before they were given Kampo treatment.RESULTS The 24 patients included 6 males and 18 females and ranged in age from 39 to 86(mean 61.2 ± 11.5) years old. Kampo formulas were individually chosen by Kampo expert doctors based on Kampo-specific diagnostics. Beneficial outcomes were obtained by Kampo treatment in 20 out of the 24 cases(83.3%). Nine out 20 cases had a major response(the numbness and pain showed improvement or reduction by 50% or more), with 7 of 9 cases showing a more than 70% symptom reduction. Eleven out of 20 cases showed a minor response(less than 50% symptom reduction), and 4 out of the 24 cases had no beneficial response. The most frequently used formula was goshajinkigan(GJG), followed by hachimijiogan(HJG) and keishibukuryogan. Thirteen of the 24 cases(54.2%) were prescribed aconite rootcontaining formulas including GJG and HJG. Aconite root has "warming" effects and ameliorates pain and numbness; 21 out of 24 cases(87.5%) in total used warming formulas such as aconite root-containing formulas to reduce CIPN.CONCLUSION Our current study suggested that Kampo formulas chosen based on Kampo-specific diagnostics could be for treating CIPN that is refractory to conventional medicine.
